Micofun-HC2%+1%

Micofun-HC 2%+1% is a fixed-dose combination topical preparation used for the short-term treatment of inflamed fungal skin infections where both antifungal and anti-inflammatory action are needed.

Established/Approved Uses

• Cutaneous candidiasis (skin infection with Candida species), including candidal intertrigo (skin-fold infections), when accompanied by significant inflammation, redness, or itching.
• Dermatophyte (tinea/ringworm) infections of the skin — such as tinea corporis, tinea cruris, and tinea pedis — when accompanied by marked inflammation or itching that warrants short-term use of a mild-to-moderate topical corticosteroid alongside an antifungal.

Adjunct/Short-Term Use

Micofun-HC 2%+1% is intended only for the initial, short-term phase of treatment (typically up to 1–2 weeks) to control inflammation and itching quickly. Once inflammation has settled, treatment is usually continued with an antifungal agent alone (without the corticosteroid) to complete the full antifungal course and reduce the risk of recurrence.

Micofun-HC 2%+1% is not intended for infections of the nails, scalp, mucous membranes, or eyes, and is not a treatment for vaginal candidiasis.

Each gram of cream/ointment typically contains:

• Miconazole nitrate — an imidazole antifungal (commonly 20 mg, i.e. 2% w/w)
• Hydrocortisone — a mild-to-moderate potency corticosteroid (commonly 10 mg, i.e. 1% w/w)

Exact strengths may vary slightly by manufacturer and formulation; always check the product label. This monograph refers to the combination as Micofun-HC 2%+1%.

Micofun-HC 2%+1% combines two active ingredients with complementary actions in a single topical cream or ointment:

• Miconazole nitrate is a broad-spectrum imidazole antifungal that is active against dermatophytes (e.g. Trichophyton, Microsporum, Epidermophyton species), yeasts (including Candida albicans), and has additional activity against some Gram-positive bacteria.
• Hydrocortisone is a mild-to-moderate potency topical corticosteroid that reduces inflammation, redness, and itching associated with the fungal infection.

The combination is designed for short-term use to rapidly relieve the inflammatory component of a fungal skin infection while the antifungal component clears the underlying infection.

Micofun-HC 2%+1% belongs to the therapeutic class of topical antifungal–corticosteroid combinations, used in dermatology for inflamed superficial fungal skin infections.

Mechanism of Action

Micofun-HC 2%+1% works through two complementary mechanisms:

• Miconazole nitrate: inhibits the fungal cytochrome P450 enzyme 14α-demethylase, blocking conversion of lanosterol to ergosterol. This depletes ergosterol, an essential component of the fungal cell membrane, increasing membrane permeability and causing leakage of cellular contents and fungal cell death (fungicidal/fungistatic depending on concentration and organism).
• Hydrocortisone: binds intracellular glucocorticoid receptors, reducing the synthesis and release of inflammatory mediators (e.g. prostaglandins, cytokines), decreasing capillary permeability, and suppressing local inflammatory cell infiltration — reducing erythema, edema, and pruritus.

Pharmacokinetics

Following topical application, systemic absorption of both miconazole and hydrocortisone through intact skin is minimal. Absorption may increase with application to broken skin, large surface areas, mucous membranes, or under occlusive dressings, particularly in infants and young children (due to a higher skin-surface-area-to-body-weight ratio).

For external (topical) use on the skin only. Wash and dry the affected area before applying Micofun-HC 2%+1%. Apply a thin layer and gently massage in. Avoid contact with the eyes, mouth, and mucous membranes. Wash hands after use unless the hands are the area being treated. Do not cover the treated area with an occlusive (airtight) dressing unless a physician specifically advises it.

Because Micofun-HC 2%+1% is applied topically and systemic absorption is minimal when used on intact skin over limited areas, clinically significant drug interactions are uncommon. However, the following should be noted:

• Oral anticoagulants (e.g. warfarin): Miconazole, even when applied topically, has rarely been reported to potentiate the effect of warfarin (increasing INR and bleeding risk), particularly with application to large areas, broken/denuded skin, or mucous membranes. Patients on warfarin who use Micofun-HC 2%+1% over extensive areas should have their INR monitored.
• Other topical corticosteroids or antifungals: Concurrent use of other topical corticosteroid-containing products on the same site is not recommended, as it may increase the risk of skin atrophy and systemic corticosteroid absorption.

Most adverse effects associated with Micofun-HC 2%+1% are local and generally mild:

• Common: burning, stinging, itching, or irritation at the application site; mild redness.
• Less common: contact dermatitis/allergic skin reaction, dryness, or a rash.
• With prolonged or inappropriate use (beyond the recommended short course, on the face, in skin folds, or under occlusion): skin atrophy (thinning), striae (stretch marks), telangiectasia (visible small blood vessels), perioral dermatitis, hypopigmentation, or acneiform eruptions, reflecting the corticosteroid component.
• Rare: systemic corticosteroid effects (e.g. adrenal suppression) have been reported very rarely with extensive, prolonged, or occluded use, especially in infants and young children.

Patients should stop use and consult a physician if irritation worsens or signs of hypersensitivity develop.

Pregnancy: Data on topical Micofun-HC 2%+1% use in pregnancy are limited. Topical corticosteroids and antifungals are generally considered lower-risk than systemic therapy owing to minimal systemic absorption, but Micofun-HC 2%+1% should be used in pregnancy only if clearly needed, at the lowest effective dose, for the shortest duration, over the smallest area, and only under medical advice — potential benefit should justify potential risk to the fetus.

Lactation: It is not known whether topically applied miconazole or hydrocortisone are excreted in clinically significant amounts in breast milk. As a precaution, avoid application to the breast/nipple area before breastfeeding, and use only under medical advice, applying to the minimum area necessary.

• Duration of use: Micofun-HC 2%+1% is intended for short-term use only (generally up to 1–2 weeks). Prolonged or repeated use, particularly of the corticosteroid component, increases the risk of skin atrophy, striae, telangiectasia, and other local corticosteroid-related adverse effects — see Side Effects.
• Site of application: Use with caution on the face, groin, and skin folds (intertriginous areas), where skin is thinner and absorption is greater; avoid prolonged use in these areas.
• Occlusion: Do not apply an occlusive (airtight) dressing over the treated area unless specifically directed by a physician, as this increases systemic absorption and the risk of local and systemic corticosteroid effects.
• Masking of infection: The corticosteroid component may mask clinical signs of untreated bacterial or viral skin infection or allow it to worsen (see Contraindications). If signs of hypersensitivity, irritation, or secondary infection develop or worsen, discontinue use and consult a physician.
• Pediatric use: Use with particular caution in infants and young children, who have a higher skin-surface-area-to-body-weight ratio and are therefore more susceptible to systemic corticosteroid absorption — see Use in Special Populations.
• Not for eye, mouth, or vaginal use.

Topical overdose with Micofun-HC 2%+1% is unlikely to cause significant systemic toxicity when used as directed on a limited skin area. Accidental ingestion or excessive/prolonged application over large areas may increase the risk of local skin adverse effects and, rarely, systemic corticosteroid effects (e.g. symptoms of adrenal suppression). If Micofun-HC 2%+1% is accidentally ingested, applied excessively, or if signs of systemic effect (unusual fatigue, weight changes) occur, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep the tube tightly closed and out of reach of children.

Pediatric Use

Micofun-HC 2%+1% may be used in children under medical supervision, generally for the shortest duration and smallest area necessary, as infants and young children have a higher skin-surface-area-to-body-weight ratio and greater potential for systemic corticosteroid absorption. Safety and efficacy in neonates and infants below 2 years have not been well established for unsupervised use; use in this age group should be directed and monitored by a physician. Avoid use with occlusive diapers/dressings in infants, as this increases absorption.

Geriatric Use

No specific dose adjustment is generally required in elderly patients, but skin in older adults may be thinner and more prone to corticosteroid-related atrophy, so use the shortest effective duration.

Renal/Hepatic Impairment

No dose adjustment is established or generally required for topical Micofun-HC 2%+1%, given minimal systemic absorption; there is no well-established renal or hepatic dosing guidance for this topical product.

Micofun-HC 2%+1% should generally be used for no longer than 1–2 weeks, or as directed by a physician. Treatment beyond this period, especially of the corticosteroid component, should only continue under direct medical supervision due to the increasing risk of skin atrophy and other local corticosteroid effects. Once inflammation resolves, therapy is usually switched to an antifungal-only agent to complete the full course of antifungal treatment.

Micofun-HC 2%+1% is classified as a topical imidazole antifungal combined with a mild-to-moderate potency corticosteroid. Miconazole nitrate belongs to the imidazole antifungal class; hydrocortisone belongs to the class of topical (low-potency) corticosteroids.

Micofun-HC 2%+1% acts through two mechanisms: miconazole nitrate inhibits fungal ergosterol synthesis (via 14α-demethylase inhibition), disrupting the fungal cell membrane and causing fungal cell death; hydrocortisone suppresses local inflammatory mediator release and immune cell activity, reducing redness, swelling, and itching associated with the infection. Together, Micofun-HC 2%+1% treats the fungal infection while providing rapid symptomatic relief of associated inflammation.

Micofun-HC 2%+1% may be used in children under medical supervision for inflamed fungal skin infections, generally applied for the shortest necessary duration and to the smallest area, because infants and young children absorb topical corticosteroids more readily than adults due to a higher skin-surface-area-to-body-weight ratio. Formal safety and efficacy data for unsupervised use in infants and very young children are limited, so use in this age group should always be directed by a physician. Avoid occlusive diapering over treated areas in infants, and avoid use on the face in young children unless specifically directed.